{"transactions":[{"id":733536,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-17T22:38:53.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":1624,"price":3.05,"value":4953.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 167,249 RSUs."}],"balance_after":295324,"source":{"system":"sec-edgar","filing":"0001610717-26-000229","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000229/form4.xml","form_type":"4"}},{"id":833189,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:21:13.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":19323,"price":6.423,"value":124111.629,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 173,082 RSUs."}],"balance_after":296948,"source":{"system":"sec-edgar","filing":"0001610717-26-000122","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000122/form4.xml","form_type":"4"}},{"id":919142,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:23:47.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":325000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001610717-26-000040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000040/form4.xml","form_type":"4"}},{"id":919141,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:23:47.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 239,987 RSUs."}],"balance_after":316271,"source":{"system":"sec-edgar","filing":"0001610717-26-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000040/form4.xml","form_type":"4"}},{"id":1030381,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T22:38:27.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":39150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":39150,"derivative":{"underlying":"Common Stock","underlying_shares":39150},"source":{"system":"sec-edgar","filing":"0001610717-25-000355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000355/form4.xml","form_type":"4"}},{"id":1030380,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T22:38:27.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":78250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":78250,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":78250},"source":{"system":"sec-edgar","filing":"0001610717-25-000355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000355/form4.xml","form_type":"4"}},{"id":1107597,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107596,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":10614,"price":2.6889,"value":28539.9846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":226271,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107595,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction represents the vesting of performance stock units (\"PSUs\") initially granted on February 2, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":236885,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107594,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":1641,"price":2.9503,"value":4841.4423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":199385,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1195473,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:33:49.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":8551,"price":0.599,"value":5122.049,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 155,821 RSUs."}],"balance_after":201026,"source":{"system":"sec-edgar","filing":"0001610717-25-000085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000085/form4.xml","form_type":"4"}},{"id":1280107,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280106,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":225000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280105,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 179,310 RSUs."}],"balance_after":209577,"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280104,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":152077,"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1425029,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1425028,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":1984,"price":1.2291,"value":2438.5344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 restricted stock units."}],"balance_after":108077,"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1425027,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 restricted stock units."}],"balance_after":110061,"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1478614,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:24:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":75000,"derivative":{"exercise_price":1.49,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000339","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000339/form4.xml","form_type":"4"}},{"id":1478613,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-14T20:24:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 RSUs."}],"balance_after":103186,"source":{"system":"sec-edgar","filing":"0001610717-24-000339","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000339/form4.xml","form_type":"4"}},{"id":1564605,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2024-03-21T20:38:57.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":2971,"price":2.0855,"value":6196.0205,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 60,310 restricted stock units."}],"balance_after":85686,"source":{"system":"sec-edgar","filing":"0001610717-24-000177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000177/form4.xml","form_type":"4"}},{"id":1674997,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-01-20T01:41:57.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000034/form4.xml","form_type":"4"}},{"id":1674996,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-20T01:41:57.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":154000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":154000,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0001610717-24-000034","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000034/form4.xml","form_type":"4"}},{"id":1674995,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2024-01-20T01:41:57.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 70,466 RSUs."}],"balance_after":88657,"source":{"system":"sec-edgar","filing":"0001610717-24-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000034/form4.xml","form_type":"4"}},{"id":1700663,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2023-12-22T21:10:48.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":1990,"price":1.3806,"value":2747.394,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,466 restricted stock units."}],"balance_after":48657,"source":{"system":"sec-edgar","filing":"0001610717-23-000419","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000419/form4.xml","form_type":"4"}},{"id":1704439,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-12-20T00:58:44.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":6875,"derivative":{"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001610717-23-000412","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000412/form4.xml","form_type":"4"}},{"id":1704438,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2023-12-20T00:58:44.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,466 restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023."}],"balance_after":50647,"source":{"system":"sec-edgar","filing":"0001610717-23-000412","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000412/form4.xml","form_type":"4"}},{"id":1944191,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2023-03-20T22:43:35.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":516,"price":1.9793,"value":1021.3188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,466 restricted stock units."}],"balance_after":37772,"source":{"system":"sec-edgar","filing":"0001140361-23-012619","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000114036123012619/form4.xml","form_type":"4"}},{"id":2030308,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance and Accounting"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-02-06T21:47:03.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-001927","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001927/doc1.xml","form_type":"4"}},{"id":2030307,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance and Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-06T21:47:03.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":75000,"derivative":{"exercise_price":2.59,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001567619-23-001927","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001927/doc1.xml","form_type":"4"}},{"id":2030306,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance and Accounting"}}],"security":"Common Stock","published_at":"2023-02-06T21:47:03.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on Febrary 2 of each year, with the first 1/3rd vesting on February 2, 2024, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 32,288 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2022."}],"balance_after":38288,"source":{"system":"sec-edgar","filing":"0001567619-23-001927","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761923001927/doc1.xml","form_type":"4"}},{"id":2186631,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance and Accounting"}}],"security":"Performance Stock Units (PSUs)","published_at":"2022-08-12T20:59:33.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":13750,"derivative":{"underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001567619-22-015864","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922015864/doc1.xml","form_type":"4"}},{"id":2186630,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance and Accounting"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-12T20:59:33.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":82500,"derivative":{"exercise_price":1.59,"expiration_date":"2032-08-09","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001567619-22-015864","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922015864/doc1.xml","form_type":"4"}}]}